Literature DB >> 12821737

The immune response against herpesvirus is more prominent in the early stages of MS.

P Villoslada1, C Juste, M Tintore, V Llorenç, G Codina, P Pozo-Rosich, X Montalban.   

Abstract

OBJECTIVE: To assess antibody levels against human herpesvirus type 6 (HHV-6), Epstein-Barr virus (EBV), and Chlamydia pneumoniae (CP) in serum from individuals in the early and late phase of MS.
RESULTS: A strong association was found between anti-HHV-6 immunoglobulin M antibodies and early MS (clinically isolated syndromes at high risk for MS, and short duration active relapsing-remitting MS) when compared with healthy controls and secondary progressive MS. Moreover, in this group of patients, titers for anti-EBV immunoglobulin G were also elevated. The authors found no association between the levels of serum antibodies against CP and MS, nor did they detect the presence of DNA for these pathogens in the serum of patients with MS. Finally, serum from two patients with other inflammatory neurologic diseases also had elevated immunoglobulin M antibodies to HHV-6, indicating that the presence of this antibody is not specific to MS.
CONCLUSION: An immune response against herpesviruses such as HHV-6 and EBV is associated with early MS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12821737     DOI: 10.1212/01.wnl.0000069461.53733.f7

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  17 in total

Review 1.  Human herpesvirus 6 infection as a trigger of multiple sclerosis.

Authors:  Konstantine I Voumvourakis; Dimitrios K Kitsos; Sotirios Tsiodras; George Petrikkos; Eleftherios Stamboulis
Journal:  Mayo Clin Proc       Date:  2010-10-06       Impact factor: 7.616

Review 2.  Epstein-barr virus: environmental trigger of multiple sclerosis?

Authors:  Jan D Lünemann; Thomas Kamradt; Roland Martin; Christian Münz
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

3.  No serological evidence for a role of HHV-6 infection in chronic fatigue syndrome.

Authors:  Peter D Burbelo; Ahmad Bayat; Jason Wagner; Thomas B Nutman; James N Baraniuk; Michael J Iadarola
Journal:  Am J Transl Res       Date:  2012-10-10       Impact factor: 4.060

4.  Asthma onset prior to multiple sclerosis and the contribution of sibling exposure in early life.

Authors:  A-L Ponsonby; T Dwyer; I van der Mei; A Kemp; L Blizzard; B Taylor; T Kilpatrick; R Simmons
Journal:  Clin Exp Immunol       Date:  2006-12       Impact factor: 4.330

Review 5.  Review part 2: Human herpesvirus-6 in central nervous system diseases.

Authors:  Karen Yao; John R Crawford; Anthony L Komaroff; Dharam V Ablashi; Steven Jacobson
Journal:  J Med Virol       Date:  2010-10       Impact factor: 2.327

6.  Murine gammaherpesvirus-68 elicits robust levels of interleukin-12 p40, but not interleukin-12 p70 production, by murine microglia and astrocytes.

Authors:  Amy Rasley; Kenneth L Bost; Ian Marriott
Journal:  J Neurovirol       Date:  2004-06       Impact factor: 2.643

Review 7.  Human Herpesviruses 6A and 6B in Brain Diseases: Association versus Causation.

Authors:  Anthony L Komaroff; Philip E Pellett; Steven Jacobson
Journal:  Clin Microbiol Rev       Date:  2020-11-11       Impact factor: 26.132

8.  Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients.

Authors:  Karen Yao; Susan Gagnon; Nahid Akhyani; Elizabeth Williams; Julie Fotheringham; Elliot Frohman; Olaf Stuve; Nancy Monson; Michael K Racke; Steven Jacobson
Journal:  PLoS One       Date:  2008-04-30       Impact factor: 3.240

9.  An attempt to investigate the presence of Epstein Barr virus in multiple sclerosis and normal control brain tissue.

Authors:  Margaret L Opsahl; Peter G E Kennedy
Journal:  J Neurol       Date:  2007-03-25       Impact factor: 4.849

Review 10.  Systematic review and meta-analysis of the sero-epidemiological association between Epstein Barr virus and multiple sclerosis.

Authors:  Yahya H Almohmeed; Alison Avenell; Lorna Aucott; Mark A Vickers
Journal:  PLoS One       Date:  2013-04-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.